Patents by Inventor Stephen M. Spaethe

Stephen M. Spaethe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for identifying and treating resistant tumors
    Publication number: 20020013370
    Abstract: This invention provides a method of identifying and reversing multidrug resistance in a multidrug resistant tumor comprising administering a multidrug resistance reversing amount of any of the compounds as defined herein.
    Type: Application
    Filed: April 17, 2001
    Publication date: January 31, 2002
    Inventors: Jason Scott Sawyer, Stephen M. Spaethe, James Jacob Starling, Gabriele Jedlitschky, Inka Leier, Dietrich Keppler
  • Methods for identifying and treating resistant tumors
    Publication number: 20020010213
    Abstract: This invention provides a method of identifying and reversing multidrug resistance in a multidrug resistant tumor comprising administering a multidrug resistance reversing amount of any of the compounds as defined herein.
    Type: Application
    Filed: April 17, 2001
    Publication date: January 24, 2002
    Inventors: Jason Scott Sawyer, Stephen M. Spaethe, James Jacob Starling, Gabriele Jedlitschky, Inka Leier, Dietrich Keppler
  • Method for treating resistant tumors
    Patent number: 5543428
    Abstract: This invention provides a method of reversing multidrug resistance in a multidrug resistance tumor comprising administering a multidrug resistance reversing amount of any of a series of phenoxy compounds as defined herein.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: August 6, 1996
    Assignee: Eli Lilly and Company
    Inventors: Jason S. Sawyer, Stephen M. Spaethe, James J. Starling
  • Benzothiophenes substituted at the 3-carbonyl
    Patent number: 5532382
    Abstract: Provided are compounds of the formula II ##STR1## wherein R.sub.6 and R.sub.7 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.5 is naphthyl, substituted nephthyl, or phenyl substituted one to three times with C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkyl, phenyl, or hydroxy; with the proviso that if the phenyl is substituted once with hydroxy, it must be further be substituted once or twice with C.sub.1 -C.sub.6 alkoxy, C.sub.l -C.sub.6 alkyl, phenyl or hydroxy, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: July 2, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
  • Benzothiophenes to inhibit leukotrienes
    Patent number: 5514704
    Abstract: A method of inhibiting leukotrienes comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 is phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe
  • Benzothiophene compounds useful for inhibiting lipoxygenase
    Patent number: 5514703
    Abstract: A method of inhibiting 5-lipoxygenase comprising administering to a mammal in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is hydrogen, or a group of the formula ##STR2## wherein R.sub.4 phenyl, substituted phenyl, naphthyl or substituted naphthyl, with the proviso that when R.sub.1 and R.sub.2 are both C.sub.1 -C.sub.6 alkyl, R.sub.3 is not hydrogen; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: May 7, 1996
    Assignee: Eli Lilly and Company
    Inventors: Donald G. Carlson, George J. Cullinan, Kennan J. Fahey, William T. Jackson, Neal W. Roehm, Stephen M. Spaethe